A mesoporous silica nanoparticulate/β-TCP/BG composite drug delivery system for osteoarticular tuberculosis therapy

Biomaterials

Volumn 32, Issue 7, 2011, Pages 1986-1995

  Zhu, Min ^a   Wang, Huixue ^b   Liu, Jiyong ^b   He, Hailong ^b   Hua, Xuguo ^b   He, Qianjun ^a   Zhang, Lingxia ^a   Ye, Xiaojian ^b   Shi, Jianlin ^a  

^a SHANGHAI INSTITUTE OF CERAMICS   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

TCP scaffolds; Antitubercular drugs; Composite drug delivery system; Controlled release; Mesoporous silica nanospheres

Indexed keywords

ANTITUBERCULAR DRUGS; BIOACTIVE GLASS COATINGS; COMPOSITE DRUG DELIVERY SYSTEM; COMPOSITE SCAFFOLDS; CONTROLLED RELEASE; DRUG CONCENTRATION; DRUG DELIVERY SYSTEM; IN-VITRO; MESO-PORES; MESOPOROUS SILICA; MESOPOROUS SILICA NANOPARTICLES; MYCOBACTERIUM TUBERCULOSIS; RELEASE PROFILES; RENAL FUNCTIONS; SORPTION ISOTHERMS; SURFACE AREA;

BIOACTIVE GLASS; BIOCOMPATIBILITY; COATINGS; DRUG THERAPY; MESOPOROUS MATERIALS; NANOSPHERES; POLYMER BLENDS; SCAFFOLDS; SILICA; SORPTION;

CONTROLLED DRUG DELIVERY;

BIOCERAMICS; CALCIUM PHOSPHATE; GLASS; ISONIAZID; NANOCOATING; NANOCOMPOSITE; RIFAMPICIN; SILICON DIOXIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG TISSUE LEVEL; EXPERIMENTAL RABBIT; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; LOW DRUG DOSE; MYCOBACTERIUM TUBERCULOSIS; NANOENCAPSULATION; NONHUMAN; POROSITY; PRIORITY JOURNAL; SPLEEN;

ANIMALS; ANTITUBERCULAR AGENTS; BIOCOMPATIBLE MATERIALS; CALCIUM PHOSPHATES; CELL LINE; DRUG DELIVERY SYSTEMS; ISONIAZID; KIDNEY; LIVER; MICE; MYCOBACTERIUM TUBERCULOSIS; NANOCOMPOSITES; NANOPARTICLES; POROSITY; RABBITS; RIFAMPIN; SILICON DIOXIDE;

MYCOBACTERIUM TUBERCULOSIS;

EID: 78650986679     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.11.025     Document Type: Article

References (50)

1. Tomioka H., Namba K. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr Pharm Design 2006, 12(31):4047-4070.
2. Vashishtha V.M. WHO global tuberculosis control report 2009: tuberculosis elimination is a distant dream. Indian Pediatr 2009, 46(5):401-402.
3. Global tuberculosis control: surveillance, planning, financing. WHO report 2008, available at: http://www.who.int/tb/publications/global_report/2008/pdf/fullreport.pdf.
4. Raviglione M.C., Gupta R., Dye C.M., Espinal M.A. The burden of drug-resistant tuberculosis and mechanisms for its control 2001, Annals of the New York Academy Science, New YorkAcademy Science, New York.
5. Huebner R.E., Castro K.G. The changing face of tuberculosis. Annu Rev Med 1995, 46:47-55.
6. Tuli S.M. Tuberculosis of the skeletal system 1997, Jaypee Brothers Medical Publishers, New Delhi, 159-160.
7. Malaviya A.N., Kotwal P.P. Arthritis associated with tuberculosis. Best Pract Res Cl Rh 2003, 17(2):319-343.
8. Mahowald M.L. Arthritis due to mycobacteria, fungi and parasites 2000, Lippincott Williams & Wilkins, Philadelphia, 2305-2320.
9. Meier J.L., Beekmann S.E. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol 1995, 7(4):329-336.
10. Puttick M.P.E., Stein H.B., Chan R.M.T. Soft tissue tuberculosis: a series of 11 cases. J Rheumatol 1995, 22:1321-1325.
11. Dutt A.K., Stead W.W. The treatment of extrapulmonary tuberculosis. Semin Resp Infect 1989, 4(3):225-231.
12. Garrido G., Gomez-Reino J.J., Fernández-Dapica P., Palenque E., Prieto S. A review of peripheral tuberculous arthritis. Semin Arthritis Rheu 1988, 18:142-149.
13. Sequeira W., Co H., Block J.A. Joint and bone tuberculosis: current diagnosis and treatment. Am J Therap 2000, 7:393-398.
14. Bass J.B., Farer L.S., Hopewell P.C., O'Brien R., Jacobs R.F., Ruben F., et al. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994, 149(5):1359-1374.
15. Davidson P.T., Le H.Q. Drug treatment of tuberculosis - 1992. Drugs 1992, 43(5):651-673.
16. Kameda K., Kawabata S., Shirai S. A case of acute hepatitis curred during treatment with isoniazid and rifampicin. Kekkaku 1980, 55:247-251. (author's transl).
17. Schaberg T. The dark side of antituberculosis therapy: adverse events involving liver function. Eur Respir J 1995, 8(8):1247-1249.
18. Agal S., Baijal R., Pramanik S., Patel N., Gupte P., Kamani P., et al. Monitoring and management of antituberculosis drug induced hepatotoxicity. J Gastroen Hepatol 2005, 20:1745-1752.
19. Yew W.W., Leung C.C. Antituberculosis drugs and hepatotoxicity. Respirology 2006, 11(6):699-707.
20. Tuli S.M. General principles of joint and bone tuberculosis. Clin Orthop Relat R 2002, 398:11-19.
21. Luk Keith D.K. Spinal tuberculosis. Curr Opin Orthop 2000, 11(3):196-201.
22. Kailasam S., Wise D.L., Gangadharam P.R.J. Bioavailability and chemotherapeutic activity of clofazimine against Mycobacterium avium complex infections in beige mice following a single implant of a biodegradable polymer. J Antimicrob Chemoth 1994, 33(2):273-279.
23. Manisha D., Khuller G.K. Sustained release of isoniazid from a single injectable dose of poly (dl-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Int J Antimicrob Ag 2001, 17:115-122.
24. Vallet-Regí M., Balas F., Arcos D. Mesoporous materials for drug delivery. Angew Chem Int Ed 2007, 46(40):7548-7558.
25. Shi X.T., Wang Y., Ren L., Gong Y., Wang D.A. Enhancing alendronate release from a novel PLGA/hydroxyapatite microspheric system for bone repairing applications. Pharm Res 2009, 26(2):422-430.
26. Tourné-Péteilh C., Lerner D.A., Charnay C., Nicole L., Bégu S., Devoisselle J.M. The potential of ordered mesoporous silica for the storage of drugs: the example of a pentapeptide encapsulated in an MSU-Tween 80. Chem Phys Chem 2003, 4(3):281-286.
27. Porter C.J., Wasan K.M., Constantinides P. Lipid-based systems for the enhanced delivery of poorly water-soluble drugs. Adv Drug Deliver Rev 2008, 60(6):615-616.
28. Sill T.J., von Recum H.A. Electrospinning: applications in drug delivery and tissue engineering. Biomaterials 2008, 29(13):1989-2006.
29. Hilder T.A., Hill J.M. Carbon nanotubes as drug delivery nanocapsules. Curr Appl Phys 2008, 8:258-261.
30. Zhang L.F., Yang D.J., Chen H.C., Sun R., Xu L., Xiong Z.C., et al. An ionically crosslinked hydrogel containing vancomycin coating on a porous scaffold for drug delivery and cell culture. Int J Pharm 2008, 353:74-87.
31. Pandey R., Sharma A., Zahoor A., Sharma A., Khuller C.K., Prasad B., et al. Poly(dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemoth 2003, 52(6):981-986.
32. Dutt M., Khuller G.K. Liposomes and PLG microparticles as sustained release antitubercular drug carriers-an in vitro and in vivo study. Int J Antimicrob 2001, 18(3):245-252.
33. Dutt M., Khuller G.K. Sustained release of isoniazid from a single injectable dose of poly (dl-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Int J Antimicrob 2001, 17(2):115-122.
34. Shi X.T., Wang Y.J., Ren L., Zhao N.R., Gong Y.H., Wang D.A., et al. Novel mesoporous silica-based antibiotic releasing scaffold for bone repair. Acta Biomater 2009, 5(5):1697-1707.
35. Vallet-Regí M., Ramila A., del Real R.P., Pariente J.P. A new property of MCM-41: drug delivery system. Chem Mater 2001, 13:308-311.
36. Doadrio A.L., Sousa E.M.B., Doadrio J.C., Pariente J.P., Barba I.I., Vallet-Regi M., et al. Mesoporous SBA-15 HPLC evaluation for controlled gentamicin drug delivery. J Control Release 2004, 97(1):125-132.
37. Initial therapy for tuberculosis in the era of multi-drug resistance: recommendation of the advisory committee for the elimination of tuberculosis. Recommendations and Reports 1993, available at: http://www.cdc.gov/mmwr/PDF/rr/rr4207.pdf.
38. Clark R. Treatment of tuberculosis: Guidelines for national programmes 2010, Perspectives in Public Health, Sage Publications Ltd., London. 4th ed.
39. Gürsoy A., Kut E., Özkíríml S. Co-encapsulation of isoniazid and rifampicin in liposomes and characterization of liposomes by derivative spectroscopy. Inter J Pharm 2004, 271:115-123.
40. Shrutidevi A., Inderjit S., Kanwal J.K., Shantaram R.B., Chaman L.K., Ramesh P., et al. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose level. Inter J Pharm 2004, 276:41-49.
41. Guo X., Wang C., Zhang Y., Xia R., Hu M., Duan C., et al. Repair of large articular cartilage defects with implants of autologous mesenchymal stem cells seeded into beta-tricalcium phosphate in a sheep model. Tissue Eng 2004, 10:1818-1829.
42. Guo X., Wang C., Duan C., Descamps M., Zhao Q., Dong L., et al. Repair of osteochondral defects with autologous chondrocytes seeded onto bioceramic scaffold in sheep. Tissue Eng 2004, 10:1830-1840.
43. Radu D.R., Lai C.Y., Jeftinija K., Rowe E.W., Jeftinija S., Lin V.S., et al. A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent. J Am Chem Soc 2004, 126(41):13216-13217.
44. Wei J., Chen F.P., Shin J.W., Hong H., Dai C.L., Liu C.S., et al. Preparation and characterization of bioactive mesoporous wollastonite-Polycaprolactone composite scaffold. Biomaterials 2009, 30:1080-1088.
45. Li X., Shi J.L., Dong X.P., Zhang L.X., Zeng H.Y. A mesoporous bioactive glass/polycaprolactone composite scaffold and its bioactivity behavior. J Biomed Mater Res A 2008, 84:84-91.
46. Mortera R., Onida B., Fiorilli S., Cauda V., Baino F., Garrone E., et al. Synthesis and characterization of MCM-41 spheres inside bioactive glass-ceramic scaffold. Chem Eng J 2008, 137:54-61.
47. Cauda V., Fiorilli S., Onida B., Vernè E., Vitale Brovarone C., Viterbo D., et al. SBA-15 ordered mesoporous silica inside a bioactive glass-ceramic scaffold for local drug delivery. J Mater Sci Mater Med 2008, 19(10):3303-3310.
48. Zhang X., Wyss U.P., Pichora D., Goosen M.F. A mechanistic study of antibiotic release from biodegradable poly (d,l-lactide) cylinders. J Control Release 1994, 31:129-144.
49. Bemer-Melchior P., Bryskier A., Drugeon H.B. Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex. J Antimicrob Chemother 2000, 46(4):571-576.
50. Rastogi N., Labrousse V., Goh K.S. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 1996, 33(3):167-175.